Stockscreener 앱 받기
18.77
2.14%
-0.41
전일 마감가:
$19.18
열려 있는:
$19.24
하루 거래량:
1.31M
Relative Volume:
0.81
시가총액:
$2.93B
수익:
$340.81M
순이익/손실:
$-419.65M
주가수익비율:
-6.586
EPS:
-2.85
순현금흐름:
$-402.10M
1주 성능:
-10.96%
1개월 성능:
+3.64%
6개월 성능:
+26.74%
1년 성능:
-11.92%
1일 변동 폭
$18.61
$20.12
1주일 범위
$18.61
$21.20
52주 변동 폭
$10.57
$23.77
Denali Therapeutics Inc Stock (DNLI) Company Profile
명칭
Denali Therapeutics Inc
전화
(650) 866-8547
주소
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
18.77 | 3.00B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-04-10 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | 재개 | Morgan Stanley | Overweight |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2025-01-07 | 개시 | Robert W. Baird | Outperform |
| 2025-01-03 | 개시 | William Blair | Outperform |
| 2024-12-16 | 업그레이드 | Stifel | Hold → Buy |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-10-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-09-06 | 개시 | B. Riley Securities | Buy |
| 2023-01-30 | 개시 | SVB Securities | Outperform |
| 2022-12-05 | 개시 | Cowen | Outperform |
| 2022-11-02 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-11-02 | 개시 | BofA Securities | Buy |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-10 | 재개 | Raymond James | Mkt Perform |
| 2021-09-21 | 개시 | Oppenheimer | Outperform |
| 2021-09-01 | 개시 | SMBC Nikko | Outperform |
| 2021-05-18 | 개시 | UBS | Buy |
| 2021-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-10 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-16 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-08-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-13 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-02-28 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-02-24 | 개시 | Jefferies | Buy |
| 2020-02-19 | 개시 | Stifel | Hold |
| 2020-01-27 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-09-26 | 개시 | Wedbush | Neutral |
| 2019-09-13 | 개시 | Nomura | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-06-26 | 개시 | H.C. Wainwright | Buy |
| 2018-11-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-11-12 | 개시 | Janney | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-01-02 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 개시 | Goldman | Neutral |
| 2018-01-02 | 개시 | JP Morgan | Overweight |
| 2018-01-02 | 개시 | Morgan Stanley | Overweight |
모두보기
Denali Therapeutics Inc 주식(DNLI)의 최신 뉴스
(DNLI) Risk Channels and Responsive Allocation - Stock Traders Daily
Ideas Watch: Is Denali Therapeutics Inc. a turnaround storyEarnings Growth Summary & Smart Money Movement Tracker - baoquankhu1.vn
Assessing Denali Therapeutics (DNLI) Valuation After WORLDSymposium Clinical Updates And Regulatory Progress - Sahm
Principal Financial Group Inc. Purchases 198,207 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (DNLI) Gets a Buy from Wedbush - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Haemonetics (HAE) and Denali Therapeutics (DNLI) - The Globe and Mail
Published on: 2026-02-08 06:47:50 - baoquankhu1.vn
Denali Therapeutics (NASDAQ:DNLI) Earns Buy Rating from BTIG Research - MarketBeat
Earnings Recap: Is Denali Therapeutics Inc forming a bullish divergenceBull Run & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Denali Therapeutics Showcases ETV Data at WORLD: TIVI PDUFA Near, DNL126 Hits 80% CSF Drop - MarketBeat
DNLI: Sustained biomarker normalization and clinical gains achieved in Hunter syndrome and MPS IIIA - TradingView
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™ - The Manila Times
Denali Therapeutics Reports Promising Clinical Trial Data for Tividenofusp Alfa and Other Enzyme Replacement Therapies in Lysosomal Storage Disorders - Quiver Quantitative
Trial data track Denali enzyme drugs for rare brain and muscle diseases - Stock Titan
A Look At Denali Therapeutics (DNLI) Valuation As New ETV Rare Disease Data Presentations Approach - Yahoo Finance
How Denali’s Brain-Targeted ETV Data and FDA Review Will Impact Denali Therapeutics (DNLI) Investors - Yahoo Finance
Denali Therapeutics Inc. (DNLI): Investor Outlook Reveals 44.49% Potential Upside In Neurodegenerative Drug Development - DirectorsTalk Interviews
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates - TradingView
Is Denali Therapeutics Inc stock suitable for long term investingJuly 2025 Sentiment & Weekly High Conviction Ideas - baoquankhu1.vn
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium - The Globe and Mail
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™ - The Manila Times
Denali to outline enzyme delivery to the brain in 2026 WORLDSymposium webcast - stocktitan.net
AlphaQuest LLC Raises Stake in Denali Therapeutics Inc. $DNLI - MarketBeat
(DNLI) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Assessing Denali Therapeutics (DNLI) Valuation As WORLDSymposium Data And FDA Priority Review Draw Closer - Sahm
Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™ - The Manila Times
Denali to present clinical data on rare disease therapies at WORLDSymposium By Investing.com - Investing.com South Africa
Denali to present clinical data on rare disease therapies at WORLDSymposium - Investing.com Nigeria
Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials - TechStock²
New enzyme studies for Hunter, Sanfilippo and Pompe at 2026 WORLDSymposium - stocktitan.net
Energy Moves: Is Denali Therapeutics Inc part of any ETFJuly 2025 Selloffs & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Denali Therapeutics (DNLI) Gets a Buy from Bank of America Securities - The Globe and Mail
REGENXBIO Delay Could Put Denali in Pole Position for Hunter Syndrome Approval - BioSpace
Stop Loss: How does Aclarion Inc Equity Warrant correlate with NasdaqJuly 2025 Rallies & Community Trade Idea Sharing Platform - baoquankhu1.vn
Denali Therapeutics Inc. (DNLI) Stock Analysis: Exploring a 59% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Short Covering: What are the future prospects of Lotterycom IncInsider Selling & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Denali Therapeutics Inc. $DNLI Shares Sold by Baillie Gifford & Co. - MarketBeat
Certain Stock Options of Denali Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 24-JAN-2026. - marketscreener.com
Denali Therapeutics (NASDAQ:DNLI) Shares Up 11.3%Here's Why - MarketBeat
Shorts Report: What are analysts price targets for Denali Therapeutics IncExit Point & AI Forecast for Swing Trade Picks - baoquankhu1.vn
3 Biotech Stocks That Could Double In 2026 - AOL.com
Stock Market Recap: What are analysts price targets for Denali Therapeutics IncJuly 2025 Rallies & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Liquidity Mapping Around (DNLI) Price Events - Stock Traders Daily
Aug Big Picture: Can Denali Therapeutics Inc withstand a market correctionRate Hike & Daily Volume Surge Signals - baoquankhu1.vn
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Buy" by Brokerages - MarketBeat
Aug Breakouts: Whats the outlook for Denali Therapeutics Incs sectorPrice Action & Community Trade Idea Sharing Platform - baoquankhu1.vn
Aug Chart Watch: Whats the outlook for Denali Therapeutics Incs sectorAnalyst Downgrade & Long Hold Capital Preservation Plans - baoquankhu1.vn
An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 40% Undervalued - 富途牛牛
Campbell & CO Investment Adviser LLC Purchases 74,066 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Aug Patterns: Can Denali Therapeutics Inc withstand a market correctionMarket Performance Recap & Weekly High Conviction Trade Ideas - baoquankhu1.vn
FOMO Trade: What makes FTRE stock attractive todayInflation Watch & Smart Allocation Stock Reports - baoquankhu1.vn
Denali Therapeutics Inc (DNLI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):